IFP Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $320K | Buy |
1,479
+328
| +28% | +$62.7K | 0.01% | 1255 |
|
|
2026
Q1 | $211K | Sell |
1,151
-55
| -5% | -$10.1K | ﹤0.01% | 1374 |
|
|
2025
Q4 | $212K | Buy |
1,206
+110
| +10% | +$18K | ﹤0.01% | 1343 |
|
|
2025
Q3 | $154K | Buy |
1,096
+11
| +1% | +$1.49K | ﹤0.01% | 1423 |
|
|
2025
Q2 | $136K | Buy |
1,085
+220
| +25% | +$27.4K | ﹤0.01% | 1466 |
|
|
2025
Q1 | $118K | Buy |
865
+70
| +9% | +$10K | ﹤0.01% | 1430 |
|
|
2024
Q4 | $122K | Buy |
795
+45
| +6% | +$7.59K | ﹤0.01% | 1373 |
|
|
2024
Q3 | $145K | Buy |
750
+13
| +2% | +$2.72K | 0.01% | 1240 |
|
|
2024
Q2 | $171K | Sell |
737
-80
| -10% | -$17.4K | 0.01% | 1118 |
|
|
2024
Q1 | $176K | Sell |
817
-1
| -0.1% | -$234 | 0.01% | 1061 |
|
|
2023
Q4 | $212K | Buy |
818
+13
| +2% | +$3.19K | 0.01% | 923 |
|
|
2023
Q3 | $207K | Sell |
805
-28
| -3% | -$7.49K | 0.01% | 947 |
|
|
2023
Q2 | $237K | Buy |
833
+248
| +42% | +$73.8K | 0.01% | 942 |
|
|
2023
Q1 | $174K | Sell |
585
-532
| -48% | -$147K | 0.01% | 1001 |
|
|
2022
Q4 | $333K | Sell |
1,117
-1,098
| -50% | -$310K | 0.01% | 1089 |
|
|
2022
Q3 | $667K | Buy |
2,215
+152
| +7% | +$32.3K | 0.02% | 791 |
|
|
2022
Q2 | $616K | Hold |
2,063
| – | – | 0.02% | 754 |
|
|
2022
Q1 | $616K | Buy |
2,063
+1,443
| +233% | +$314K | 0.02% | 754 |
|
|
2021
Q4 | $151K | Sell |
620
-10,232
| -94% | -$2.63M | ﹤0.01% | 1084 |
|
|
2021
Q3 | $3.08M | Buy |
10,852
+318
| +3% | +$104K | 0.06% | 191 |
|
|
2021
Q2 | $3.65M | Buy |
10,534
+548
| +5% | +$166K | 0.08% | 156 |
|
|
2021
Q1 | $2.79M | Buy |
9,986
+2,154
| +28% | +$581K | 0.05% | 172 |
|
|
2020
Q4 | $1.9M | Buy |
7,832
+1,085
| +16% | +$280K | 0.08% | 218 |
|
|
2020
Q3 | $1.91M | Buy |
6,747
+534
| +9% | +$149K | 0.11% | 173 |
|
|
2020
Q2 | $1.63M | Buy |
6,213
+5,313
| +590% | +$1.6M | 0.13% | 170 |
|
|
2020
Q1 | $276K | Sell |
900
-833
| -48% | -$253K | 0.03% | 475 |
|
|
2019
Q4 | $525K | Buy |
1,733
+183
| +12% | +$50.8K | 0.04% | 421 |
|
|
2019
Q3 | $356K | Buy |
+1,550
| New | +$361K | 0.02% | 578 |
|
|
2019
Q1 | $112K | Sell |
487
-644
| -57% | -$203K | 0.02% | 649 |
|
|
2018
Q4 | $332K | Sell |
1,131
-256
| -18% | -$81.7K | 0.02% | 676 |
|
|
2018
Q3 | $490K | Sell |
1,387
-94
| -6% | -$32.4K | 0.02% | 664 |
|
|
2018
Q2 | $430K | Sell |
1,481
-1,787
| -55% | -$502K | 0.02% | 727 |
|
|
2018
Q1 | $1.04M | Hold |
3,268
| – | – | 0.05% | 383 |
|
|
2017
Q4 | $1.04M | Sell |
3,268
-62
| -2% | -$19.9K | 0.05% | 382 |
|
|
2017
Q3 | $1.04M | Buy |
3,330
+1,066
| +47% | +$316K | 0.04% | 432 |
|
|
2017
Q2 | $614K | Buy |
2,264
+146
| +7% | +$38.6K | 0.03% | 599 |
|
|
2017
Q1 | $579K | Buy |
2,118
+174
| +9% | +$49.2K | 0.03% | 614 |
|
|
2016
Q4 | $551K | Buy |
1,944
+570
| +41% | +$169K | 0.03% | 579 |
|
|
2016
Q3 | $430K | Buy |
1,374
+6
| +0.4% | +$1.78K | 0.02% | 620 |
|
|
2016
Q2 | $331K | Buy |
1,368
+881
| +181% | +$232K | 0.02% | 737 |
|
|
2016
Q1 | $112K | Sell |
487
-2,023
| -81% | -$534K | 0.02% | 649 |
|
|
2015
Q4 | $769K | Buy |
+2,510
| New | +$721K | 0.05% | 370 |
|
Other funds holding BIIB
IFP Advisors's BIIB Position: Q2 2026 in Review
IFP Advisors increased its Biogen (BIIB) stake by 28% in Q2 2026, buying an estimated $62.7K and bringing the position to 1,479 shares worth $320K. The position accounts for 0.01% of the portfolio, ranked #1255.
IFP Advisors first reported a position in BIIB in Q4 2015 and has held it in 42 quarters since. The position peaked at $3.65M in Q2 2021. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- IFP Advisors held 1,479 shares of Biogen worth $320K as of Q2 2026.
- IFP Advisors bought 328 Biogen shares in Q2 2026, an estimated $62.7K.
- Biogen made up 0.01% of IFP Advisors's portfolio in Q2 2026, its #1255 holding.
- IFP Advisors first reported a position in Biogen in Q4 2015 and has held it in 42 quarters since.
- IFP Advisors's Biogen position peaked at $3.65M in Q2 2021.
- 1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.